These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23709685)

  • 1. Current management of sickle cell anemia.
    McGann PT; Nero AC; Ware RE
    Cold Spring Harb Perspect Med; 2013 Aug; 3(8):. PubMed ID: 23709685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle cell disease in children.
    Meier ER; Miller JL
    Drugs; 2012 May; 72(7):895-906. PubMed ID: 22519940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
    Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
    Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How I use hydroxyurea to treat young patients with sickle cell anemia.
    Ware RE
    Blood; 2010 Jul; 115(26):5300-11. PubMed ID: 20223921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
    Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
    Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
    [No Abstract]   [Full Text] [Related]  

  • 9. Sickle cell disease in North Europe.
    Howard J; Davies SC
    Scand J Clin Lab Invest; 2007; 67(1):27-38. PubMed ID: 17365983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is therapeutic progress in the management of sickle cell disease applicable in sub-Saharan Africa?].
    De Montalembert M; Tshilolo L
    Med Trop (Mars); 2007 Dec; 67(6):612-6. PubMed ID: 18300525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
    Chaturvedi S; DeBaun MR
    Am J Hematol; 2016 Jan; 91(1):5-14. PubMed ID: 26547630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
    Upadhye DS; Jain DL; Trivedi YL; Nadkarni AH; Ghosh K; Colah RB
    PLoS One; 2016; 11(1):e0147081. PubMed ID: 26785407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
    Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sickle cell disease--pathophysiology and treatment.
    Redding-Lallinger R; Knoll C
    Curr Probl Pediatr Adolesc Health Care; 2006; 36(10):346-76. PubMed ID: 17055417
    [No Abstract]   [Full Text] [Related]  

  • 16. Current and emerging treatments for sickle cell disease.
    Monus T; Howell CM
    JAAPA; 2019 Sep; 32(9):1-5. PubMed ID: 31460979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.
    Lê PQ; Ferster A; Cotton F; Vertongen F; Vermylen C; Vanderfaeillie A; Dedeken L; Heijmans C; Ketelslegers O; Dresse MF; Gulbis B
    Med Trop (Mars); 2010 Dec; 70(5-6):467-70. PubMed ID: 21516988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial.
    Sánchez LM; Nieves RM; Latham T; Stuber S; Luden JR; Urcuyo GS; Berges ME; Florencio C; Gonzalez C; Del Villar P; Lane A; Schultz W; Jeste N; Mena R; Ware RE
    Blood Adv; 2018 Nov; 2(Suppl 1):50-53. PubMed ID: 30504201
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
    J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.